A CONSISTENT AND TOLERABLE
SAFETY PROFILE1
MOST ADVERSE EVENTS in ALINA WERE MILD-TO-MODERATE (Grades 1–2)1
ALINA: Adverse events occurring in ≥15% of patients2

ALINA: Adverse events occurring in ≥15% of patients2

- No unexpected safety findings were observed; no Grade 5 (fatal) adverse events were reported1
- Median treatment duration was 23.9 months for ALECENSA and 2.1 months for chemotherapy1
The safety profile of ALECENSA in resected ALK+ NSCLC was consistent with the established ALECENSA safety profile1,3–5
*The safety-evaluable population included patients who underwent randomisation and received any amount of ALECENSA or platinum-based chemotherapy. AEs are listed according to Medical Dictionary for Regulatory Activities preferred term.1 Multiple occurrences of the same AE in an individual patient are counted only once.1
AE: adverse event; ALK: anaplastic lymphoma kinase; COVID-19: coronavirus disease 2019; NSCLC: non-small cell lung cancer; SmPC: Summary of Product Characteristics.
1. Wu Y-L, et al. N Engl J Med 2024;390(14):1265–1276; 2. Solomon BJ, et al. Presented at the European Society for Medical Oncology Congress, 20–24 October 2023, Madrid, Spain; 3. Hida T, et al. Lancet 2017;390(10089):29–39; 4. Peters S, et al. N Engl J Med 2017;377(9):829–838; 5. Zhou C, et al. Lancet Respir Med 2019;7(5):437–446.